Skin autofluorescence is associated with severity of vascular complications in Japanese patients with Type2 diabetes

Diabetic Medicine

Volumn 29, Issue 4, 2012, Pages 492-500

  Tanaka, K ^a   Tani, Y ^a   Asai, J ^a   Nemoto, F ^a   Kusano, Y ^a   Suzuki, H ^a   Hayashi, Y ^a   Asahi, K ^a   Nakayama, M ^a   Miyata, T ^b   Watanabe, T ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Advanced glycation end products; Diabetes; Vascular

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALBUMIN; HEMOGLOBIN A1C;

ADULT; AGED; ALBUMIN BLOOD LEVEL; AORTA DISEASE; ARTICLE; BRAIN INFARCTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CROSS-SECTIONAL STUDY; DIABETIC RETINOPATHY; DISEASE DURATION; DISEASE SEVERITY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; ISCHEMIC HEART DISEASE; JAPANESE; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MICROANGIOPATHY; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NON INVASIVE PROCEDURE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; RISK ASSESSMENT; SKIN AUTOFLUORESCENCE; SYSTOLIC BLOOD PRESSURE;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD PRESSURE; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DIABETIC NEUROPATHIES; DIABETIC RETINOPATHY; FEMALE; FLUORESCENCE; GLYCOSYLATION END PRODUCTS, ADVANCED; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SKIN; SMOKING;

EID: 84863251714     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2011.03448.x     Document Type: Article

References (30)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type2 diabetes (UKPDS33). Lancet 1998; 352: 837-853.
3. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with Type2 diabetes (UKPDS34). Lancet 1998; 352: 854-865.
4. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005; 54: 1615-1625.
5. Ramasamy R, Vannucci SJ, Yan SS, Herold K, Yan SF, Schmidt AM. Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology 2005; 15: 16R-28R.
6. 1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Control and Complications Trial. Diabetes 1999; 48: 870-880.
7. Gerrits EG, Lutgers HL, Kleefstra N, Graaff R, Groenier KH, Smit AJ et al. Skin autofluorescence: a tool to identify Type2 diabetic patients at risk for developing microvascular complications. Diabetes Care 2008; 31: 517-521.
8. Meerwaldt R, Lutgers HL, Links TP, Graaff R, Baynes JW, Gans RO et al. Skin autofluorescence is a strong predictor of cardiac mortality in diabetes. Diabetes Care 2007; 30: 107-112.
9. Tanaka K, Tani Y, Asai J, Nemoto F, Kusano Y, Suzuki H et al. Skin autofluorescence is associated with renal function and cardiovascular diseases in pre-dialysis chronic kidney disease patients. Nephrol Dial Transplant 2011; 26: 214-220.
10. Tanaka K, Katoh T, Asai J, Nemoto F, Suzuki H, Asahi K et al. Relationship of skin-autofluorescence to cardiovascular disease in Japanese hemodialysis patients. Ther Apher Dial 2010; 14: 334-340.
11. Yue X, Hu H, Koetsier M, Graaff R, Han C. Reference values for the Chinese population of skin autofluorescence as a marker of advanced glycation end products accumulated in tissue. Diabet Med 2010; 28: 818-823.
12. Seino Y, Nanjo K, Tajima N, Kadowaki T, Kashiwagi A, Araki E et al. The Committee of the Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus; Report of the committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Invest 2010; 1: 212-228.
13. Hoelzel W, Weykamp C, Jeppsson JO, Miedema K, Barr JR, Goodall I et al. IFCC reference system for measurement of hemoglobin A1c in human blood and the national standardization schemes in the United States, Japan, and Sweden: a method-comparison study. Clin Chem 2004; 50: 166-174.
14. Sacks DB; ADA/EASD/IDF Working Group of the HbA1c Assay. Global harmonization of hemoglobin A1c. Clin Chem 2005; 51: 681-683.
15. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K et al. Revised equations for eGFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53: 982-992.
16. Meerwaldt R, Graaff R, Oomen PH, Links TP, Jager JJ, Alderson NL et al. Simple non-invasive assessment of advanced glycation end product accumulation. Diabetologia 2004; 47: 1324-1330.
17. Meerwaldt R, Links T, Graaff R, Thorpe SR, Baynes JW, Hartog J et al. Simple noninvasive measurement of skin autofluorescence. Ann N Y Acad Sci 2005; 1043: 290-298.
18. Mulder DJ, Water TV, Lutgers HL, Graaff R, Gans RO, Zijlstra F et al. Skin autofluorescence, a novel marker for glycemic and oxidative stress-derived advanced glycation endproducts: an overview of current clinical studies, evidence, and limitations. Diabetes Technol Ther 2006; 8: 523-535.
19. Meerwaldt R, Hartog J, Graaff R, Huisman RJ, Links TP, den Hollander NC et al. Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. J Am Soc Nephrol 2005; 16: 3687-3693.
20. Ueno H, Koyama H, Tanaka S, Fukumoto S, Shinohara K, Shoji T et al. Skin autofluorescence, a marker for advanced glycation end product accumulation, is associated with arterial stiffness in patients with end-stage renal disease. Metabolism 2008; 57: 1452-1457.
21. Ueno H, Koyama H, Fukumoto S, Tanaka S, Shoji T, Emoto M et al. Advanced glycation end products, carotid atherosclerosis, and circulating endothelial progenitor cells in patients with end-stage renal disease. Metabolism 2010; 60: 453-459.
22. Matsumoto T, Tsurumoto T, Baba H, Osaki M, Enomoto H, Yonekura A et al. Measurement of advanced glycation endproducts in skin of patients with rheumatoid arthritis, osteoarthritis, and dialysis-related spondyloarthropathy using non-invasive methods. Rheumatol Int 2007; 28: 157-160.
23. Ohnuki Y, Nagano R, Takizawa S, Takagi S, Miyata T. Advanced glycation end products in patients with cerebral infarction. Inter Med 2009; 48: 587-591.
24. Miyata T, Fu MX, Kurokawa K, van Ypersele de Strihou C, Thorpe SR, Baynes JW. Autoxidation products of both carbohydrates and lipids are increased in uremic plasma: is there oxidative stress in uremia? Kidney Int 1998; 54: 1290-1295.
25. Sugiyama S, Miyata T, Ueda Y, Tanaka H, Maeda K, Kawashima S et al. Plasma levels of pentosidine in diabetic patients: an advanced glycation end product. J Am Soc Nephrol 1998; 9: 1681-1688.
26. Gerrits EG, Smit AJ, Bilo HJ. AGEs, autofluorescence and renal function. Nephrol Dial Transplant 2009; 24: 710-713.
27. Na R, Stender IM, Henriksen M, Wulf HC. Autofluorescence of human skin is age-related after correction for skin pigmentation and redness. J Invert Dermatol 2001; 116: 536-540.
28. Joshi D, Gupta R, Dubey A, Shiwalkar A, Pathak P, Gupta RC et al. TRC4186, a novel AGE-breaker, improves diabetic cardiomyopathy and nephropathy in Ob-ZSF1 model of type2 diabetes. J Cardiovasc Pharmacol 2009; 54: 72-81.
29. Coughlan MT, Forbes JM, Cooper ME. Role of the AGE crosslink breaker, alagebrium, as a renoprotective agent in diabetes. Kidney Int Suppl 2007; 72: S54-S60.
30. Forbes JM, Thallas V, Thomas MC, Founds HW, Burns WC, Jerums G et al. The breakdown of pre-existing advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. FASEB J 2003; 17: 1762-1764.